Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.
about
Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine.Cardiovascular disease in adult survivors of childhood cancer.An update on cardio-oncology.Individual prediction of heart failure among childhood cancer survivors.Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation SurvivorsHuman induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.Pharmacogenomics and adverse drug reactions in children.Treatment-related cardiotoxicity in survivors of childhood cancer.The emerging era of pharmacogenomics: current successes, future potential, and challenges.A Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic Malignancies.Prevention of cardiotoxicity among survivors of childhood cancer.Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.Pharmacogenetics of anthracyclines.Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine.Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy.Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia.Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction.Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening.Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients.Hypertension Susceptibility Loci are Associated with Anthracycline-related Cardiotoxicity in Long-term Childhood Cancer Survivors.Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.Patient-Specific Pluripotent Stem Cells in Doxorubicin Cardiotoxicity: A New Window Into Personalized Medicine.Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer.A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer.Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.Clinical prediction models for anthracycline-associated cardiotoxicity among pediatric cancer survivors--ready for prime time?Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial.Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma.Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.CATCH-KB: Establishing a Pharmacogenomics Variant Repository for Chemotherapy-Induced Cardiotoxicity.Determining the genetic basis of anthracycline-cardiotoxicity by molecular response QTL mapping in induced cardiomyocytes.Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.Using Zebrafish for Investigating the Molecular Mechanisms of Drug-Induced CardiotoxicityGenetic variants inSLC22A17 and SLC22A7are associated with anthracycline-induced cardiotoxicity in children
P2860
Q33671281-80387E7A-FB3A-4E86-9954-968141886086Q33900003-49ACA0A2-5EEC-42A7-BE9C-380D3D83BC53Q34042984-86A557FA-8493-462E-925A-ED6D0930D4B0Q34650059-490C1E76-0475-443F-A948-C06A9C21CF89Q35040680-2CF6713B-E304-44D4-90FA-958B6C439446Q35562745-F81620CD-0FC3-4A2A-862E-E2490757BF87Q36004460-C4958571-6931-46EB-9396-91BE455FE927Q37159230-0DC40649-EFA7-4F71-AA6D-A86E69138803Q37378179-E94E06BA-8B8A-4F81-AADA-CF089B1B0268Q37421271-B5399640-BC97-4DB6-B74C-ABE6EC0BC69BQ37719025-79DAEAC2-242F-49A2-9DBB-E5EAA264E12CQ38156036-0C14CFC4-B938-4C68-9F40-98BBC682EE31Q38200683-4E5DA688-2F3F-48BC-9B40-CBD44BD3A35CQ38545052-47996AB4-AFED-4824-BFC1-9E2963877CBCQ38824644-9BD322A6-E659-4F03-8677-96EE4270094BQ38838517-DDD08CE5-16C7-4177-AD6C-1D2D038CF7E1Q38856218-832AB8E5-E7BF-4E2C-9B4A-70237AB2F8C5Q38874111-B9480AB8-3340-4773-94C4-BE2CFA338550Q38888350-CB16AB7C-FA77-4273-9613-6C6D62E5FBDCQ38895172-756FF300-3852-48D1-935B-84E4DC8465EEQ39078275-C526F0F0-6AED-4FDE-8820-F22ABE70234FQ39420843-434A38A4-64BB-4597-BCE0-2ED5FA675319Q40039502-62430D98-41B3-48ED-ABD2-825DBAC9A274Q40065987-270B0264-5B98-49B1-BBD6-83DF8E0FCD9CQ41430035-4A44E0D0-839E-4FEE-9CC3-2F35E8803AFDQ42130469-9B9A9168-E4A6-40E5-A43F-700DAC321C31Q46343364-AD83F023-636E-43DE-B2E7-4C0985C6C8F5Q47112444-D86CFC31-743F-481B-91D5-265AF926BA9BQ49136273-28EF27EA-537F-498C-AE01-DE58B3701ADAQ50481250-09E8F9A6-589C-45C7-BFB9-58364BB472B9Q51816225-BC9A26F1-091A-40AA-B491-7807CE672E04Q53564509-CE40C168-6BD4-4639-A93D-10D3AD0E02B0Q53672562-147E7FCD-C071-4B57-B1B3-3C83DF776403Q55208199-6F825462-2052-49ED-9E20-A614A723F602Q55291410-151E65E9-D7EA-4BDD-BEC3-72A1097B91C4Q55518023-010A090A-BDF0-4398-BFEF-013E40CF2115Q58548679-8F39586D-4F58-4C22-AA27-402472D48DD3Q58862883-CA6A84C3-CB9E-46FC-8B9B-961436E0B9D5
P2860
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Validation of variants in SLC2 ...... ed cardiotoxicity in children.
@en
Validation of variants in SLC2 ...... ed cardiotoxicity in children.
@nl
type
label
Validation of variants in SLC2 ...... ed cardiotoxicity in children.
@en
Validation of variants in SLC2 ...... ed cardiotoxicity in children.
@nl
prefLabel
Validation of variants in SLC2 ...... ed cardiotoxicity in children.
@en
Validation of variants in SLC2 ...... ed cardiotoxicity in children.
@nl
P2093
P2860
P356
P1476
Validation of variants in SLC2 ...... ced cardiotoxicity in children
@en
P2093
B C Carleton
C J D Ross
CPNDS Consortium
E C van Dalen
H J van der Pal
H Visscher
L C Kremer
M J Rieder
M R Hayden
P2860
P304
P356
10.1002/PBC.24505
P577
2013-02-25T00:00:00Z